<DOC>
	<DOCNO>NCT00782574</DOCNO>
	<brief_summary>A Phase I study assess safety tolerability AZD2281 combination Cisplatin patient advance Solid Tumours . This open label-dose finding ; establish maximum tolerate dose AZD2281 combine Cisplatin patient advance solid tumour . Approximately 50 ( max 60 ) patient 2 country enrol .</brief_summary>
	<brief_title>Phase I AZD2281/Cisplatin Advanced Solid Tumour Patients</brief_title>
	<detailed_description />
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Life expectancy least 12 week Histologically confirm metastatic cancer , amenable surgery radiation therapy curative intent Patients measurable non measurable disease accord RECIST Less 28 day active therapy ( ie treatment use treat disease ) high dose radiotherapy Brain Metastases spinal cord compression unless irradiate least 4 week entry stable without steroid treatment &gt; 1 week Persistent CTCAE Grade 2 great toxicity ( exclude alopecia ) cause prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced solid tumour</keyword>
	<keyword>Poly ( ADP ribose ) polymerase</keyword>
	<keyword>homologous deficiency</keyword>
	<keyword>BRCA1</keyword>
</DOC>